ClinicalTrials.gg
RecruitingNCT05558605AGILE-EchoUpdated Sep 30, 2026

Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment

An interventional study of AI-guided echo and Standard echo in Heart Failure and Valve Heart Disease, sponsored by Baker Heart and Diabetes Institute. Recruiting at 1 site in Australia. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Baker Heart and Diabetes Institute · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.
Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 167 studies in Heart Failure with a site in Australia — 26 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.

Planned enrollment
52nd of 135
612 · median 350
Started
2023
with 4 others
No phase
57 of 167
14 open now
Primary completion
2027-06
later than 23 of 40 live
Registered
135th of 167
by date

Among the 167 studies in Heart Failure with a site in Australia, this one is the 52nd largest by planned enrollment of the 135 interventional ones that give a count, is one of 5 that started in 2023, is one of 57 with no phase, reaches primary completion later than 23 of the 40 other live ones, and was the 135th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

26 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Heart Failure with a site in Australia, or all of them as a file.
02

Study summary

Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.

Read the detailed description

Heart Failure (HF) and valvular heart disease (VHD) are disproportionate problems in rural and remote Australia (RRA) relative to the rest of the country, due in part to an ageing rural population and to the frequency of rheumatic heart disease in the Aboriginal community. Late diagnoses can lead to avoidable hospital admissions and expense to the Australian health system. Echocardiography is the imaging investigation of choice, and a cornerstone of management, but access to this essential test shows huge geographic variations in Australia. The primary reason for this is the dependence of this technique on expert acquisition. Artificial intelligence (AI) has now been harnessed to optimise echocardiographic image acquisition, and secure, cloud-based storage enables remote measurement and interpretation. This trial seeks to demonstrate the effectiveness of AI-based echocardiography-guided triage and management of patients with known or suspected heart disease in RRA. This study will involve the conduct of a world-first randomised controlled trial of AI-testing and early intervention to detect early stages of HF and VHD, select appropriate management, reduce admissions and preserve functional status and quality of life. The study will be conducted with partipants in RRA, aged 40 years and older with at least one HF risk factor and recruited through clinic and community outreach in four sites with the involvement of remote outreach from i) Alice Springs Hospitals, ii) Nepean Hospital to Dubbo Hospital and Western NSW, iii) Princess Alexandra Hospital to Roma, Charleville and Western Queensland, and iv) Perth Aboriginal communities in partnership with the Royal Perth hospital and the Derbarl Yerrigan Health Service. Approximately 1200 individuals at risk for HF and VHD will be screened and followed up. The study will be conducted in partnership with Aboriginal community partners.

03

Conditions studied

  • Heart Failure
  • Valve Heart Disease

Keywords

  • Artificial intelligence
  • Echocardiography
  • Heart failure
  • Valve disease
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >45 years
  • eligible for Medicare
  • exercise intolerance or cardiovascular (CV) risk factors

Exclusion criteria

Exclusion Criteria:

  • Known HF or HVD
  • situations where cardio-protection is already indicated (eg. known CAD)
  • comorbid conditions with \<2 years
  • inability to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
612 participants (estimated)

Study arms

  • Experimental
    Screening/Management Plan

    AI-guided echo acquisition performed using a desktop echo machine (uSmart 3300, Terason, Burlington, MA) with AI software (Caption Health, Brisbane, CA) obtained by a non-expert (eg. clinic nurse, registrar general practitioner or physician) at the remote clinic, usually on the day of clinic review. Images will then be uploaded onto a secure cloud and downloaded at the core lab for measurement, interpretation and reporting.

    Diagnostic Test: AI-guided echo

  • Active comparator
    Usual care

    Standard echo acquisition by a sonographer either at a referral hospital, or by a visiting team - usually necessitating a delay. Measurement, interpretation and reporting will happen as usual.

    Diagnostic Test: Standard echo

Interventions

  • Diagnostic testAI-guided echo

    AI-guided echocardiography

  • Diagnostic testStandard echo

    Standard echocardiography

06

What researchers measure

Primary outcomes

  1. Diagnosis of cardiac dysfunction or heart valve disease

    Number of Participants with Diagnosis of cardiac dysfunction or heart valve disease

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Alice Springs Hospital
    Alice Springs, Northern Territory, Australia
    Recruiting
    • Angus Baumann, MD · Contact
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.

Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 52 months is above that.

Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2022
First posted
Sep 28, 2022
StartActual
Feb 24, 2023
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Jun 30, 2027was Jun 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Jun 30, 2027
Sep 30, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Jun 30, 2026→Jun 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05558605
Lead sponsor
Baker Heart and Diabetes Institute
Collaborators
Alice Springs Hospital, Princess Alexandra Hospital, Brisbane, Australia, Royal Perth Hospital, Ochre Health, Walgett Aboriginal Medical Services, Merriden Health Service, Royal Hobart Hospital, Quairading Medical Practice
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Feb 24, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Tom Marwick, MBBS, PhD
Contact
tom.marwick@baker.edu.au
+61385321550
Tom Marwick, MBBS, PhD
principal investigator · Baker Heart and Diabetes Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion